Only a few glucagon infusion studies have been conducted in patients with metabolic-associated disease, and very few compare the effects of glucagon on metabolism in healthy volunteers with its effects on patients with obesity and/or MASLD (Table 1). This evidence concerns the gene GCG and obesity disorder.